PMID: 8944334Jan 1, 1996Paper

Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay

Breast Cancer Research and Treatment
Christian M KurbacherD Krebs

Abstract

Apart from clinical trials, mitoxantrone (MX) is rarely used in breast cancer (BC) due to the anticipated anthracycline cross-resistance. We have examined this drug versus doxorubicin (DOX) using data obtained from in vitro microplate ATP tumor chemosensitivity assays (ATP-TCA) of BC cells which were derived from 55 chemotherapy-naive patients at time of primary surgery. Both drugs were tested at 6 different concentrations ranging from 6.25% to 200% peak plasma concentration in vivo (PPC). Differences between DOX and MX observed for mean IC50, IC90, and a sensitivity index (SI) were not statistically significant. In vitro response rates were 44% for DOX and 52% for MX. 34 of 52 eligible assays (65%) showed comparable activity of both drugs whereas a lack of cross-resistance was observed in the remaining 18 (35%) tumors as indicated by differences for SI. Cumulative concentration-response plots of tumors responding in vitro with a > or = 50 percent or > or = 90 percent tumor cell inhibition showed a strong dose-dependence for both DOX and MX at concentrations which normally can be achieved within clinical tumors (i.e. 6.25%-50% PPC). At higher concentrations, however, cytotoxicity of DOX and MX could not be improved by further i...Continue Reading

References

Jan 16, 1975·The New England Journal of Medicine·B FisherE R Fisher
Feb 19, 1976·The New England Journal of Medicine·G BonadonnaU Veronesi
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·L J PierceK H Cowan
Dec 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D D Von HoffC F LeMaistre
May 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I C HendersonD Henry
Dec 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L AhmannJ N Ingle
Sep 1, 1988·Gynecologic Oncology·B U SevinH E Averette
May 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A NeidhartD Young
Jul 1, 1987·In Vitro Cellular & Developmental Biology : Journal of the Tissue Culture Association·F R AhmannS Rodney
Feb 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R B JonesA Strashun
Jan 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E JonesS E Salmon
Mar 1, 1985·Drug Intelligence & Clinical Pharmacy·G DuKartA Yacobi
Oct 1, 1982·Cancer·J SandbachM Obrien
Jan 1, 1995·Journal of Bioluminescence and Chemiluminescence·R D PettyI A Cree
Feb 15, 1995·JAMA : the Journal of the American Medical Association·G BonadonnaP Valagussa
Nov 1, 1994·Journal of Bioluminescence and Chemiluminescence·P E AndreottiH W Bruckner

❮ Previous
Next ❯

Citations

Sep 23, 2000·Anti-cancer Drugs·M H NealeI A Cree
Nov 15, 2001·Anti-cancer Drugs·T SchöndorfC M Kurbacher
Aug 21, 2002·Anti-cancer Drugs·Christian M KurbacherPeter E Andreotti
Jul 20, 2005·BMC Cancer·Federica Di NicolantonioIan A Cree
Jul 23, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ian A Cree
Oct 2, 2007·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Engin UlukayaMeral Demirci
Sep 11, 2010·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Michael E SughrueAndrew T Parsa
Jan 11, 2007·British Journal of Cancer·M SchmidtJ G Hengstler
Nov 29, 2001·Melanoma Research·M H NealeI A Cree
Nov 1, 1996·Cancer·I A CreeM Untch
Dec 13, 2019·Journal of Tissue Engineering·Wei LiaoYi Gao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.